文献速递肝病消化道肿瘤与早癌

肝细胞癌血管侵犯的基因组分析揭示分子驱动因素与预测生物标志物

Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers.
PubMed 文献 · Hepatology · 2021-05-08

该研究利用TCGA肝细胞癌数据(n=373)分析血管侵犯(VI)的基因组、转录组和蛋白质组特征,发现MYC癌基因是VI相关分子改变的共同上游调控因子,FN1/fibronectin在人和小鼠侵袭性HCC中保守且促进癌细胞迁移侵袭,血浆fibronectin在HCC患者中显著升高,提示其可作为VI的无创蛋白质组学生物标志物。

要点

  • MYC是HCC血管侵犯相关mRNA、miRNA和蛋白质组改变的共同上游调控因子。
  • Fibronectin(FN1)是跨物种保守的侵袭性HCC蛋白质组生物标志物。
  • 血浆fibronectin在HCC患者中显著高于肝硬化患者,具无创预测潜力。

核心结论

  • HCC血管侵犯存在由MYC驱动的独特转录、表观遗传和蛋白质组改变,MYC上调fibronectin表达促进HCC侵袭性,fibronectin是有前景的VI无创蛋白质组学生物标志物。

研究设计与样本

  • 利用TCGA多平台癌症基因组数据(n=373)评估伴血管侵犯肿瘤的基因组、转录组和蛋白质组图谱。
  • 对侵袭性人HCC与MYC驱动的小鼠HCC进行比较蛋白质组分析。
  • 使用独立人HCC组织微阵列(n=153)验证fibronectin组织过表达,并检测血浆fibronectin水平(HCC n=35,肝硬化 n=10)。

主要发现

  • TCGA肝细胞癌队列中大血管侵犯占5%(n=17),微血管侵犯占25%(n=94)。
  • MYC癌基因是VI相关mRNA、miRNA和蛋白质组改变的共同上游调控因子。
  • 小鼠Fn1(P=1.7×10^-11)和人FN1(P=1.5×10^-4)为跨物种保守的侵袭性HCC蛋白质组生物标志物。
  • FN1促进HCC癌细胞的迁移和侵袭表型。
  • 人HCC组织微阵列(n=153;P<0.001)显示fibronectin组织过表达;血浆fibronectin在HCC患者(n=35;均值=307.7 μg/mL;SEM=35.9)中显著高于肝硬化患者(n=10;均值=41.8 μg/mL;SEM=13.3;P<0.0001)。

临床怎么用

  • 血浆fibronectin可能作为HCC血管侵犯的无创蛋白质组学生物标志物,用于风险分层辅助决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Vascular invasion (VI) is a critical risk factor for HCC recurrence and poor survival. The molecular drivers of vascular invasion in HCC are open for investigation. Deciphering the molecular landscape of invasive HCC will help identify therapeutic targets and noninvasive biomarkers. APPROACH AND RESULTS: To this end, we undertook this study to evaluate the genomic, transcriptomic, and proteomic profile of tumors with VI using the multiplatform cancer genome atlas (The Cancer Genome Atlas; TCGA) data (n = 373). In the TCGA Liver Hepatocellular Carcinoma cohort, macrovascular invasion was present in 5% (n = 17) of tumors and microvascular invasion in 25% (n = 94) of tumors. Functional pathway analysis revealed that the MYC oncogene was a common upstream regulator of the mRNA, miRNA, and proteomic changes in VI. We performed comparative proteomic analyses of invasive human HCC and MYC-driven murine HCC and identified fibronectin to be a proteomic biomarker of invasive HCC (mouse fibronectin 1 [Fn1], P = 1.7 × 10-11 ; human FN1, P = 1.5 × 10-4 ) conserved across the two species. Mechanistically, we show that FN1 promotes the migratory and invasive phenotype of HCC cancer cells. We demonstrate tissue overexpression of fibronectin in human HCC using a large independent cohort of human HCC tissue microarray (n = 153; P < 0.001). Lastly, we showed that plasma fibronectin levels were significantly elevated in patients with HCC (n = 35; mean = 307.7 μg/mL; SEM = 35.9) when compared to cirrhosis (n = 10; mean = 41.8 μg/mL; SEM = 13.3; P < 0.0001). CONCLUSIONS: Our study evaluates the molecular landscape of tumors with VI, identifying distinct transcriptional, epigenetic, and proteomic changes driven by the MYC oncogene. We show that MYC up-regulates fibronectin expression, which promotes HCC invasiveness. In addition, we identify fibronectin to be a promising noninvasive proteomic biomarker of VI in HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Krishnan MS, Rajan Kd A, Park J, et al. Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. Hepatology. 2021. PMID: 33140851. doi:10.1002/hep.31614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。